Cochlear (COH) Trading update summary
Event summary combining transcript, slides, and related documents.
Trading update summary
6 May, 2026Business performance and market dynamics
Sales and profit are lower due to weaker demand in developed markets, especially among adults and seniors, and disruptions in emerging markets, notably the Middle East due to conflict.
Developed market growth, particularly in cochlear implants, is below expectations, with adult and senior segment growth likely under 5% for the year.
Hospital system pressures in Europe, especially the UK and Germany, have led to longer waiting lists, industrial action, and deprioritization of cochlear implant surgeries.
Consumer sentiment in the U.S. is at a historic low, impacting both referrals and conversion rates for hearing treatments.
Hearing aid sales trends are closely correlated with cochlear implant sales, amplifying revenue variability.
Regional and segment-specific challenges
Middle East sales are impacted by war, leading to order cancellations, reduced surgeries, logistical constraints, and increased receivables risk.
China faces premium product sales pressure due to withdrawn reimbursement in special access zones.
Services and Acoustics segments are performing in line with or above expectations, with Q3 services revenue up 13% and acoustics up 11% in constant currency.
Pediatric segment in developed markets is now less than 30% of sales, with recent declines in the U.S. and flat performance in Europe.
Financial implications and guidance
FY26 underlying net profit guidance reduced to $290-330 million, down from previous $435-460 million, reflecting lower sales, margin pressure, and FX impacts.
Lower sales and manufacturing output, along with a stronger Australian dollar, are pressuring profitability.
Gross margin guidance has been revised down to 72%, with a one percentage point reduction expected to impact net profit by $20 million.
Second half constant currency sales growth is guided at 2%-6%, with ongoing uncertainty in developed markets and the Middle East.
Cost base reshaping and stronger AUD expected to further impact net profit by $18-25 million and $25 million respectively.
Latest events from Cochlear
- Underlying net profit fell 9% despite stable revenue, with a stronger second half expected.COH
H1 202613 Feb 2026 - Record profit and revenue growth, robust outlook, and continued investment in innovation.COH
H2 20241 Feb 2026 - Record financial results, board renewal, and innovation drive strong growth and future outlook.COH
AGM 202418 Jan 2026 - Sales and profit up, services down; cloud spend and new launches shape cautious outlook.COH
H1 20258 Jan 2026 - Strong implant growth and Nexa launch drive results, offset by services decline and China headwinds.COH
H2 202523 Nov 2025 - Sales, profit, and dividends rose; R&D, board renewal, and global growth remain priorities.COH
AGM 202523 Oct 2025